Core Viewpoint - The company announced a capital increase agreement involving existing shareholders and several investors, which will lead to a significant reduction in its ownership stake in a subsidiary, 同源康生物, from approximately 57.14% to 39.03% [1] Group 1: Capital Increase Details - The total consideration for the capital increase is approximately RMB 83.5 million, which will increase the registered capital of 同源康生物 by about RMB 6.49 million [1] - Following the capital increase, the total registered capital of 同源康生物 will rise from RMB 14 million to approximately RMB 20.49 million [1] Group 2: Strategic Implications - 同源康生物 is a biopharmaceutical company focused on dual antibodies, triple antibodies, and ADC, and will no longer be a subsidiary of the group after the capital increase [1] - The capital increase is expected to provide operational funding for 同源康生物, which is in an early-stage startup phase and will require significant funding before achieving commercialization [1] - This transaction allows the group to concentrate its resources on other operational aspects while retaining a significant interest and level of participation in 同源康生物 [1]
同源康医药-B：同源康生物将获增资8350万元